Phaseline

Targets › XE

XE: drug programs, companies and trials

2 programs from 2 companies in 4 trials: 2 Phase 2, 2 Phase 1; Other, Respiratory, Oncology; next expected readout Jan 2027.

Open in Phaseline: the race on XE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sean FainXenon MRI
MRI contrast agent using hyperpolarized xenon to assess regional lung ventilation and perf
XEPhase 2Imaging TechniquesJan 2027
University of VirginiaHyperpolarized Xenon-129 MRI
Inhaled hyperpolarized xenon-129 contrast agent for lung ventilation imaging via MRI
XEPhase 2Lung Transplant Rejection; Chronic Obstructive Pulmonary Disease; E-Cig UseMar 2029

Conditions

Lung Transplant Rejection (1) Chronic Obstructive Pulmonary Disease (1) E-Cig Use (1) Imaging Techniques (1)

Modalities

small molecule (2)

Companies

University of Virginia (1) Sean Fain (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.